The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Hornick, John R ^a   Xu, Jinbin ^a   Vangveravong, Suwanna ^a   Tu, Zhude ^a   Mitchem, Jonathan B ^a   Spitzer, Dirk ^a   Goedegebuure, Peter ^a,b   Mach, Robert H ^a   Hawkins, William G ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; GEMCITABINE; LIGAND; REACTIVE OXYGEN METABOLITE; SIGMA 2 OPIATE RECEPTOR; SIRAMESINE; SV 119; SW 43; UNCLASSIFIED DRUG; DEOXYCYTIDINE; DRUG DERIVATIVE; SIGMA OPIATE RECEPTOR; SIGMA-2 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER GROWTH; CELL VIABILITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PANCREAS CANCER; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CELL SURVIVAL; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; METABOLISM; PANCREAS TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; RECEPTORS, SIGMA;

EID: 78549265187     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-298     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-49. 10.3322/caac.20006, 19474385.
2. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899-903.
3. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230:776-82. 10.1097/00000658-199912000-00006, 1420941, 10615932.
4. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350:1200-10. 10.1056/NEJMoa032295, 15028824.
5. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297:267-77. 10.1001/jama.297.3.267, 17227978.
6. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008, 299:1019-26. 10.1001/jama.299.9.1019, 18319412.
7. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-13.
8. Kashiwagi H, McDunn JE, Simon PO, Goedegebuure PS, Xu J, Jones L, Chang K, Johnston F, Trinkaus K, Hotchkiss RS, Mach RH, Hawkins WG. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer 2007, 6:48. 10.1186/1476-4598-6-48, 1939854, 17631687.
9. Kashiwagi H, McDunn JE, Simon PO, Goedegebuure PS, Vangveravong S, Chang K, Hotchkiss RS, Mach RH, Hawkins WG. Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma. J Transl Med 2009, 7:24. 10.1186/1479-5876-7-24, 2669042, 19323815.
10. Su TP. Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther 1982, 223:284-90.
11. Quirion R, Hammer RP, Herkenham M, Pert CB. Phencyclidine (angel dust)/sigma "opiate" receptor: visualization by tritium-sensitive film. Proc Natl Acad Sci USA 1981, 78:5881-5. 10.1073/pnas.78.9.5881, 348895, 6272322.
12. Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, Rothman RB, Su TP, Tam SW, Taylor DP. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 1992, 13:85-6. 10.1016/0165-6147(92)90030-A, 1315463.
13. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa C, Rice KC. Sigma receptors: biology and function. Pharmacol Rev 1990, 42:355-402.
14. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 1994, 268:9-18. 10.1016/0922-4106(94)90115-5, 7925616.
15. Matsumoto RR. Sigma receptors: historical perspective and background. Sigma receptors: chemistry, cell biology, and clinical implications 2007, 1. New York: Springer, Su TP, Matsumoto RR, Bowen WD.
16. Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA 1996, 93:8072-7. 10.1073/pnas.93.15.8072, 38877, 8755605.
17. Seth P, Leibach FH, Ganapathy V. Cloning and structural analysis of the cDNA and the gene encoding the murine type 1 sigma receptor. Biochem Biophys Res Commun 1997, 241:535-40. 10.1006/bbrc.1997.7840, 9425306.
18. de Costa BR, Bowen WD, Hellewell SB, Walker JM, Thurkauf A, Jacobson AE, Rice KC. Synthesis and evaluation of optically pure [3H]-(+)-pentazocine, a highly potent and selective radioligand for sigma receptors. FEBS Lett 1989, 251:53-8. 10.1016/0014-5793(89)81427-9, 2568952.
19. Bowen WD, De Costa B, Hellewell SB, Thurkauf A, Walker JM, Rice KC. Characterization of [3H] (+)-pentazocine, a highly selective sigma ligand. Prog Clin Biol Res 1990, 328:117-20.
20. Matsumoto RR, Bowen WD, Tom MA, Vo VN, Truong DD, de Costa BR. Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol 1995, 280:301-10. 10.1016/0014-2999(95)00208-3, 8566098.
21. Gebreselassie D, Bowen WD. Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes. Eur J Pharmacol 2004, 493:19-28. 10.1016/j.ejphar.2004.04.005, 15189760.
22. Xu J, Tu Z, Jones LA, Vangveravong S, Wheeler KT, Mach RH. [3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: a novel sigma-2 receptor probe. Eur J Pharmacol 2005, 525:8-17. 10.1016/j.ejphar.2005.09.063, 16289030.
23. Tu Z, Xu J, Jones LA, Li S, Zeng D, Kung MP, Kung HF, Mach RH. Radiosynthesis and biological evaluation of a promising sigma(2)-receptor ligand radiolabeled with fluorine-18 or iodine-125 as a PET/SPECT probe for imaging breast cancer. Appl Radiat Isot 2010, 68:2268-73. 10.1016/j.apradiso.2010.06.004, 20594864.
24. Bem WT, Thomas GE, Mamone JY, Homan SM, Levy BK, Johnson FE, Coscia CJ. Overexpression of sigma receptors in nonneural human tumors. Cancer Res 1991, 51:6558-62.
25. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995, 55:408-13.
26. Mach RH, Wheeler KT. Development of molecular probes for imaging sigma-2 receptors in vitro and in vivo. Cent Nerv Syst Agents Med Chem 2009, 9:230-45. 2802455, 20021357.
27. Vilner BJ, de Costa BR, Bowen WD. Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability. J Neurosci 1995, 15:117-34.
28. Ostenfeld MS, Fehrenbacher N, Hoyer-Hansen M, Thomsen C, Farkas T, Jaattela M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res 2005, 65:8975-83. 10.1158/0008-5472.CAN-05-0269, 16204071.
29. Wei Z, Mousseau DD, Dai Y, Cao X, Li XM. Haloperidol induces apoptosis via the sigma2 receptor system and Bcl-XS. Pharmacogenomics J 2006, 6:279-88.
30. Rybczynska AA, Dierckx RA, Ishiwata K, Elsinga PH, van Waarde A. Cytotoxicity of sigma-receptor ligands is associated with major changes of cellular metabolism and complete occupancy of the sigma-2 subpopulation. J Nucl Med 2008, 49:2049-56. 10.2967/jnumed.108.053876, 18997057.
31. Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 2002, 62:313-22.
32. Groth-Pedersen L, Ostenfeld MS, Hoyer-Hansen M, Nylandsted J, Jaattela M. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res 2007, 67:2217-25. 10.1158/0008-5472.CAN-06-3520, 17332352.
33. Heading C. Siramesine H Lundbeck. Curr Opin Investig Drugs 2001, 2:266-70.
34. Parry MJ, Alakoskela JM, Khandelia H, Kumar SA, Jaattela M, Mahalka AK, Kinnunen PK. High-affinity small molecule-phospholipid complex formation: binding of siramesine to phosphatidic acid. J Am Chem Soc 2008, 130:12953-60. 10.1021/ja800516w, 18767848.
35. Fruhwirth GO, Hermetter A. Mediation of apoptosis by oxidized phospholipids. Subcell Biochem 2008, 49:351-67. full_text, 18751918.
36. Salvayre R, Auge N, Benoist H, Negre-Salvayre A. Oxidized low-density lipoprotein-induced apoptosis. Biochim Biophys Acta 2002, 1585:213-21.
37. Barrera G, Pizzimenti S, Dianzani MU. Lipid peroxidation: control of cell proliferation, cell differentiation and cell death. Mol Aspects Med 2008, 29:1-8. 10.1016/j.mam.2007.09.012, 18037483.
38. Zeng C, Vangveravong S, Xu J, Chang KC, Hotchkiss RS, Wheeler KT, Shen D, Zhuang ZP, Kung HF, Mach RH. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res 2007, 67:6708-16. 10.1158/0008-5472.CAN-06-3803, 17638881.
39. Vangveravong S, Xu J, Zeng C, Mach RH. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor ligands. Bioorg Med Chem 2006, 14:6988-97. 10.1016/j.bmc.2006.06.028, 16837201.
40. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995, 376:37-43. 10.1038/376037a0, 7596430.
41. Thornberry NA. The caspase family of cysteine proteases. Br Med Bull 1997, 53:478-90.
42. Garcia-Calvo M, Peterson EP, Rasper DM, Vaillancourt JP, Zamboni R, Nicholson DW, Thornberry NA. Purification and catalytic properties of human caspase family members. Cell Death Differ 1999, 6:362-9. 10.1038/sj.cdd.4400497, 10381624.
43. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995, 184:39-51. 10.1016/0022-1759(95)00072-I, 7622868.
44. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP, Schabel FM. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984, 44:717-26.